CN111471193A - Dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel and preparation method thereof - Google Patents
Dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel and preparation method thereof Download PDFInfo
- Publication number
- CN111471193A CN111471193A CN202010541765.1A CN202010541765A CN111471193A CN 111471193 A CN111471193 A CN 111471193A CN 202010541765 A CN202010541765 A CN 202010541765A CN 111471193 A CN111471193 A CN 111471193A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- collagen
- dialdehyde
- hydrogel
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 89
- 108010035532 Collagen Proteins 0.000 title claims abstract description 89
- 229920001436 collagen Polymers 0.000 title claims abstract description 89
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 79
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 79
- 239000000017 hydrogel Substances 0.000 title claims abstract description 60
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 55
- -1 Dialdehyde polysaccharide Chemical class 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000007864 aqueous solution Substances 0.000 claims abstract description 33
- 239000000243 solution Substances 0.000 claims abstract description 32
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims abstract description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 25
- 238000003756 stirring Methods 0.000 claims abstract description 18
- 150000004676 glycans Chemical class 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 235000010493 xanthan gum Nutrition 0.000 claims description 13
- 239000000230 xanthan gum Substances 0.000 claims description 13
- 229920001285 xanthan gum Polymers 0.000 claims description 13
- 229940082509 xanthan gum Drugs 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 235000012000 cholesterol Nutrition 0.000 claims description 12
- QNEPTKZEXBPDLF-JDTILAPWSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] carbonochloridate Chemical compound C1C=C2C[C@@H](OC(Cl)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNEPTKZEXBPDLF-JDTILAPWSA-N 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 6
- 230000018044 dehydration Effects 0.000 claims description 6
- 238000006297 dehydration reaction Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 238000001338 self-assembly Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000002262 Schiff base Substances 0.000 claims description 4
- 150000004753 Schiff bases Chemical class 0.000 claims description 4
- 238000010382 chemical cross-linking Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 102000012422 Collagen Type I Human genes 0.000 claims description 3
- 108010022452 Collagen Type I Proteins 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 2
- 239000004373 Pullulan Substances 0.000 claims description 2
- 229920001218 Pullulan Polymers 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 229960002086 dextran Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 235000019423 pullulan Nutrition 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical group N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 abstract description 17
- 239000003431 cross linking reagent Substances 0.000 abstract description 8
- 230000002209 hydrophobic effect Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 239000011258 core-shell material Substances 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 150000004804 polysaccharides Chemical class 0.000 description 19
- 229920000642 polymer Polymers 0.000 description 14
- 229920002085 Dialdehyde starch Polymers 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 5
- 125000003172 aldehyde group Chemical group 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000019426 modified starch Nutrition 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000012620 biological material Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000005232 molecular self-assembly Methods 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 150000001263 acyl chlorides Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000010972 isotropic cell growth Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2303/00—Characterised by the use of starch, amylose or amylopectin or of their derivatives or degradation products
- C08J2303/04—Starch derivatives
- C08J2303/10—Oxidised starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2489/00—Characterised by the use of proteins; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel and a preparation method thereof. Firstly, carrying out cholesterol group hydrophobic modification on polysaccharide, then specifically oxidizing the polysaccharide by utilizing sodium periodate to prepare an amphiphilic polysaccharide derivative with a dialdehyde structure, and then self-assembling the amphiphilic polysaccharide derivative in an aqueous solution to form dialdehyde polysaccharide nano-particles with a core-shell structure; then mixing and stirring 3-6% of dialdehyde polysaccharide nano-particle solution and 0.4-0.9% of collagen solution according to the volume ratio of 1 (0.5-1.5), and standing at 30-37 ℃ for 24h to prepare the dialdehyde polysaccharide nano-particle crosslinked collagen hydrogel. The invention has the advantages that: the green and harmless dialdehyde polysaccharide nano-particles are used as a cross-linking agent, and the prepared hydrogel has uniform aperture, good mechanical property and good biocompatibility, and has good application prospect in the field of tissue engineering scaffold materials.
Description
Technical Field
The invention relates to the technical field of hydrogel, in particular to dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel which has uniform pore diameter, good mechanical property and good biocompatibility and can be applied to the fields of medical dressings, drug release and tissue scaffolds, and a preparation method of the hydrogel.
Background
Collagen (Collagen) is the most abundant protein in animals, about one third of the protein in the body, and is widely present in the tissues of skin, cartilage, tendon, visceral intercellular substance and ligament of mammals. The glue has excellent performances of low immunogenicity, good biocompatibility, biodegradability and the like, so that the glue can be widely applied to the fields of biological materials such as wound dressings, drug delivery carriers, tissue engineering, cosmetics and the like. Collagen of 27 different structures has now been found, of which type I collagen is the one found in all types of collagen with the highest content (about 90% of the total collagen in the organism), the most widespread, the most studied and the most widely used.
Under physiological conditions, collagen can self-assemble to form collagen fibers, which can further form a three-dimensional network structure and bind water filled in the collagen fibers, so that the solution is converted into hydrogel. The highly hydrated network-like structure of collagen hydrogels behaves like natural tissue and is biodegradable. Therefore, the application of collagen hydrogel in the field of tissue engineering has attracted a great deal of attention. Researchers hope that collagen hydrogel can be used as a temporary substitute material for extracellular matrix to realize in vitro cell culture and tissue regeneration. Therefore, the collagen hydrogel is often used as a tissue filler, a scaffold material and a drug carrier and widely applied to the biomedical fields of tissue engineering, wound dressing, drug sustained release and the like. However, the application of pure collagen hydrogels is often limited by their poor mechanical properties, high swelling capacity, and excessively fast biodegradation rate. The chemical crosslinking modification can enable the interior of the collagen hydrogel to form a compact space network structure, thereby effectively improving the defects. Thus, glutaraldehyde, polyphenols and oxidized polysaccharides are generally used as cross-linking agents to immobilize collagen to overcome the above disadvantages. However, due to rapid crosslinking reaction, electrostatic interaction, hydrogen bonding, etc., local flocculation inevitably occurs once collagen is contacted with a crosslinking agent, which affects the uniform spatial network structure inside the collagen hydrogel, and further affects the physical and chemical properties of the hydrogel. Based on the above, the invention provides a collagen hydrogel which is prepared by using novel dialdehyde polysaccharide nanoparticles as a cross-linking agent and chemically cross-linking and modifying collagen and has the advantages of high mechanical strength, low swelling degree and good biocompatibility.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel and a preparation method thereof, and solves the defects in the prior art.
In order to realize the purpose, the technical scheme adopted by the invention is as follows:
a dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel, comprising: the collagen hydrogel is prepared by mixing and stirring uniformly a collagen aqueous solution with the mass fraction of 0.4-0.9% prepared from type I collagen and a dialdehyde polysaccharide nano-particle aqueous solution with the mass fraction of 3-6% prepared from dialdehyde polysaccharide nano-particles according to the mass ratio of 1 (0.5-1.5), and based on the chemical crosslinking reaction activity of Schiff base.
The invention also discloses a preparation method of the dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel, which comprises the following steps:
(1) preparing an aqueous collagen solution: dissolving I type collagen in 0.25M acetic acid aqueous solution to prepare collagen aqueous solution with the mass fraction of 0.4-0.9%, and then slowly adjusting the pH value of the collagen aqueous solution to be neutral under the ice-bath condition by using 2M sodium hydroxide solution;
(2) preparing dialdehyde polysaccharide nanoparticle solution: dissolving 1-5 parts by mass of polysaccharide in 50 parts by mass of molten imidazole under the condition of stirring in an oil bath at 100 ℃, and stabilizing for 30min to prepare a 1-10% clear and transparent polysaccharide solution; adding cholesteryl chloroformate (the molar ratio of the cholesteryl chloroformate to a polysaccharide molecular dehydration unit (AGU) is (0.005-0.05): 1) into the system, stirring for 1-3 h at 90-110 ℃, precipitating with excessive ethanol after the reaction is finished, filtering and washing for 4-6 times, and drying at 40-70 ℃ to obtain the amphiphilic polysaccharide derivative; dispersing amphiphilic polysaccharide derivatives in water to obtain a polysaccharide derivative solution with the mass concentration of 1% -10%, adding sodium periodate (the molar ratio of sodium periodate to AGU is 0.1-1.0), reacting at 30-45 ℃ in the dark for 2-5 h, dialyzing after the reaction is finished, and freeze-drying to prepare the cholesterol grafted amphiphilic dialdehyde polysaccharide derivative; directly dissolving the amphiphilic dialdehyde polysaccharide derivative into deionized water to carry out self-assembly to obtain dialdehyde polysaccharide nano-particle aqueous solution with the mass fraction of 3-6%;
(3) preparation of collagen-based hydrogel: and (2) taking the collagen aqueous solution with the mass fraction of 0.4-0.9%, adding the dialdehyde polysaccharide nano-particle aqueous solution with the mass fraction of 3-6% under the ice bath condition, mixing and stirring uniformly according to the mass ratio of 1 (0.5-1.5), and standing at 30-37 ℃ for 24h to prepare the polysaccharide nano-crosslinked collagen hydrogel.
Preferably, the polysaccharide is any one or a mixture of starch, hydroxyethyl starch, sodium alginate, xanthan gum, pullulan, dextran, chitosan, guar gum and carrageenan.
Compared with the prior art, the invention has the advantages that:
(1) the collagen hydrogel is prepared by crosslinking and modifying collagen through the dialdehyde polysaccharide nano particles, so that the problems of collagen flocculation caused by rapid reaction, electrostatic interaction and the like of a crosslinking agent and the collagen can be effectively overcome, the problems of cytotoxicity and the like caused by free precipitation of a micromolecular aldehyde crosslinking agent can be avoided, and the application requirement in the field of biological materials is met.
(2) According to the dialdehyde polysaccharide nano-particle crosslinked collagen hydrogel provided by the invention, aldehyde groups of dialdehyde polysaccharide nano-particles can react with amino groups of collagen to perform Schiff base reaction so as to chemically crosslink and modify the collagen, so that a compact space network structure is formed; more importantly, the dialdehyde polysaccharide nano particles can be used as a nano particle filler to further improve the mechanical strength, the swelling degree, the biodegradation performance and the like of the collagen hydrogel.
(3) The coating of the micromolecule medicine can be realized in the process of forming the dialdehyde polysaccharide nano-particles through molecular self-assembly, and further the dialdehyde polysaccharide nano-particles are endowed with the function of directional administration of the cross-linked collagen hydrogel.
Drawings
Fig. 1 is an SEM photograph of dialdehyde starch-cholesterol nanoparticles:
(A) and (B) photographs of different degrees of oxidation for the same amount of cholesterol grafted (0.01mol/mol AGU): (A) degree of oxidation of 46%, (B) degree of oxidation of 87%; (C) and (D) photographs of different amounts of cholesterol grafted for the same degree of oxidation (46%): (C)0.005mol/mol AGU, (D)0.02mol/mol AGU;
FIG. 2 is an SEM photograph of different hydrogels after lyophilization; (A) pure collagen hydrogel (Col), (B) oxidized starch cross-linked modified collagen hydrogel (OS/Col), (C) dialdehyde starch-cholesterol nanoparticle cross-linked modified collagen hydrogel (ocnps/Col);
FIG. 3 is a graph of stress-strain curves and compressive failure strength in compression mode for different hydrogel samples; (A) a stress-strain curve (B) compression failure strength comparison graph;
FIG. 4 is a schematic diagram showing the cell viability of L929 cells cultured in different hydrogel extracts for 24h and 72 h;
FIG. 5 is a bright field micrograph and a fluorescence micrograph of L929 cells stained with calcein cell stain after 24h incubation on different hydraulic surfaces, with the bright field micrograph on the left and the fluorescence micrograph on the right.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in further detail by referring to the following examples.
The dialdehyde polysaccharide nanoparticle cross-linking agent is prepared by a simple, convenient, green and efficient method. In molten imidazole, the polysaccharide-cholesterol polymer is prepared by esterification reaction of acyl chloride group of cholesterol chloroformate as hydrophobic agent and hydroxyl group on the polysaccharide molecular skeleton chain. Molten imidazole can rapidly and completely dissolve polysaccharides, providing a homogeneous reaction medium, which is an important condition for producing polysaccharide esters of higher purity. Imidazole is used as a solvent in a reaction system and also used as a reaction medium to participate in the formation of an imidazole-cholesterol compound intermediate, and the intermediate is favorable for the next step of rapid and complete reaction with polysaccharide molecules, so that the reaction rate is greatly improved. In addition, imidazole is used as a basic substance to bind with hydrochloric acid, which is a by-product obtained from the reaction, to promote the forward progress of the esterification reaction. Only about one percent of hydroxyl groups of polysaccharide molecules are occupied in the esterification reaction, so that enough ortho-dihydroxy groups are remained for the subsequent sodium periodate oxidation reaction to normally carry out. The sodium periodate can specifically oxidize ortho-dihydroxy in the polysaccharide-cholesterol polymer into aldehyde group to prepare the dialdehyde polysaccharide-cholesterol polymer. By a direct dissolution method, the amphiphilic polymer dialdehyde polysaccharide-cholesterol polymer is self-assembled to form dialdehyde polysaccharide nano-particles on the premise of not introducing any organic solvent and ensuring the green and safe product. The intramolecular or intermolecular attraction between the hydrophobic segments of cholesterol facilitates the self-assembly process of the amphiphilic polymer. The cholesterol of the hydrophobic segment tends to gather at the core of the particle, while the hydrophilic dialdehyde polysaccharide chain forms the shell of the particle, and the hydrophilic shell plays a role in protecting the inner core and enhances the water solubility of the dialdehyde polysaccharide nano particle. The dialdehyde polysaccharide nano-particles not only can chemically cross-link and modify collagen, but also can further improve the physical and chemical properties of the collagen hydrogel due to the characteristics of nano-scale size and high specific surface area. In addition, in the process of forming dialdehyde polysaccharide nano-particles by molecular self-assembly, the coating of small molecular drugs can be realized, and the hydrogel prepared by crosslinking collagen has the function of directional administration. Therefore, the application of the prepared collagen hydrogel in the fields of biological materials and the like by taking the dialdehyde polysaccharide nano particles as the cross-linking agent has advantages.
The invention takes natural biological macromolecules as raw materials, firstly, cholesterol is chemically grafted on polysaccharide molecular chains in fused imidazole, and the polysaccharide-cholesterol polymer is prepared. Then, the polysaccharide is specifically oxidized by sodium periodate to prepare the dialdehyde polysaccharide-cholesterol polymer. Then, the amphiphilic polymer dialdehyde polysaccharide-cholesterol polymer is used for self-assembly to form dialdehyde polysaccharide nano-particles. The particle size of the dialdehyde polysaccharide nano-particles is controlled by adjusting the introduction amount of cholesterol and aldehyde groups in the dialdehyde polysaccharide-cholesterol polymer. Based on the chemical crosslinking reactivity of Schiff base between aldehyde group of dialdehyde polysaccharide nano-particles and amino group of collagen molecules, dialdehyde polysaccharide nano-particle crosslinked collagen hydrogel with excellent physicochemical property and good biocompatibility is prepared.
Example 1
(1) Preparing an aqueous collagen solution: dissolving collagen in 0.25M acetic acid aqueous solution to prepare collagen acetic acid aqueous solution with mass fraction of 0.6%, and slowly adjusting pH to be neutral by 2M sodium hydroxide solution under ice bath condition to obtain collagen aqueous solution.
(2) Preparing dialdehyde starch nanoparticle solution: under the condition of oil bath stirring at 100 ℃, 5 parts by mass of soluble starch is dissolved in 50 parts by mass of molten imidazole and is stabilized for 30min to prepare a 10% clear and transparent starch solution. Adding cholesteryl chloroformate (wherein the molar ratio of cholesteryl chloroformate to starch molecule dehydration unit (AGU) is 0.02:1) into the system, stirring at 100 deg.C for 1h, precipitating with excessive ethanol after reaction, filtering, washing for 5 times, and oven drying at 60 deg.C to obtain amphiphilic starch derivative. Dispersing the amphiphilic starch derivative in water to obtain a polysaccharide derivative solution with the mass concentration of 8%, adding sodium periodate (wherein the molar ratio of the sodium periodate to AGU is 0.5:1), reacting at 37 ℃ in the dark for 4 hours, dialyzing and freeze-drying after the reaction is finished to prepare the cholesterol grafted amphiphilic dialdehyde starch derivative, and directly dissolving the amphiphilic dialdehyde starch derivative in deionized water to self-assemble to obtain the dialdehyde starch nanoparticle aqueous solution with the mass fraction of 4%.
(3) Preparation of collagen-based hydrogel: taking the neutral collagen solution with the mass fraction of 0.6% after the pH is adjusted, adding the dialdehyde starch nanoparticle aqueous solution with the mass fraction of 4% under the ice bath condition, mixing and stirring uniformly according to the mass ratio of 1:1.2, and incubating for 24h at 30 ℃ to obtain the dialdehyde starch nano cross-linked collagen hydrogel.
Example 2
(1) Preparing an aqueous collagen solution: dissolving collagen in 0.25M acetic acid aqueous solution to prepare collagen acetic acid aqueous solution with the mass fraction of 0.5%, and slowly adjusting the pH to be neutral by using 2M sodium hydroxide solution under the ice-bath condition to obtain the collagen aqueous solution.
(2) Preparing dialdehyde xanthan gum nanoparticle solution: under the condition of stirring in an oil bath at 100 ℃, 4 parts by mass of soluble starch is dissolved in 50 parts by mass of molten imidazole and is stabilized for 30min to prepare a clear and transparent xanthan gum solution with the concentration of 8%. Adding cholesteryl chloroformate (wherein the molar ratio of cholesteryl chloroformate to xanthan gum molecular dehydration unit (AGU) is 0.04:1) into the system, stirring at 90 deg.C for 2.5h, precipitating with excessive ethanol after reaction, filtering, washing for 5 times, and oven drying at 40 deg.C to obtain amphiphilic xanthan gum derivative. Dispersing amphiphilic xanthan gum derivatives in water by ultrasonic to obtain a xanthan gum derivative solution with the mass concentration of 6%, adding sodium periodate (wherein the molar ratio of the sodium periodate to AGU is 0.4:1), reacting for 4 hours at 40 ℃ in a dark place, dialyzing and freeze-drying after the reaction is finished to prepare the cholesterol grafted amphiphilic dialdehyde xanthan gum derivatives, dispersing the amphiphilic dialdehyde xanthan gum derivatives in deionized water by using a probe type ultrasonic instrument, and self-assembling to obtain the dialdehyde xanthan gum nanoparticle aqueous solution with the mass fraction of 4%.
(3) Preparation of collagen-based hydrogel: and (3) taking the neutral collagen solution with the mass fraction of 0.5% after the pH is adjusted, adding a dialdehyde xanthan gum nanoparticle aqueous solution with the mass fraction of 4% under an ice bath condition, mixing and stirring uniformly according to the mass ratio of 1:1, and incubating for 24h at 37 ℃ to obtain the dialdehyde xanthan gum nano cross-linked collagen hydrogel.
Example 3
(1) Preparing an aqueous collagen solution: dissolving collagen in 0.25M acetic acid aqueous solution to prepare collagen acetic acid aqueous solution with mass fraction of 0.6%, and slowly adjusting pH to be neutral by 2M sodium hydroxide solution under ice bath condition to obtain collagen aqueous solution.
(2) Preparing a dialdehyde alginic acid nanoparticle solution: under the condition of stirring in an oil bath at 100 ℃, 3 parts by mass of soluble starch is dissolved in 50 parts by mass of molten imidazole and is stabilized for 30min to prepare a 6% clear and transparent sodium alginate solution. Adding cholesteryl chloroformate (wherein the molar ratio of cholesteryl chloroformate to sodium alginate molecular dehydration unit (AGU) is 0.01:1) into the system, stirring at 100 ℃ for 1.5h, precipitating with excessive ethanol after the reaction is finished, centrifuging to remove supernatant, washing for 5 times, centrifuging, precipitating, and drying at 40 ℃ to obtain the amphiphilic sodium alginate derivative. Dispersing the amphiphilic sodium alginate derivative in a water/ethanol mixed solution to obtain a polysaccharide derivative solution with the mass concentration of 4%, adding sodium periodate (wherein the molar ratio of the sodium periodate to AGU is 1:1), reacting for 4 hours at 40 ℃ in the dark, dialyzing and freeze-drying after the reaction is finished to obtain the cholesterol grafted amphiphilic dialdehyde sodium alginate derivative, and directly dissolving the amphiphilic dialdehyde sodium alginate derivative in deionized water to prepare a dialdehyde starch nanoparticle aqueous solution with the mass fraction of 2% through ultrasonic self-assembly.
(3) Preparation of collagen-based hydrogel: taking the neutral collagen solution with the mass fraction of 0.6% after the pH is adjusted, adding the dialdehyde starch nanoparticle aqueous solution with the mass fraction of 2% under the ice bath condition, mixing and stirring uniformly according to the mass ratio of 1:1, and incubating for 24h at 37 ℃ to obtain the dialdehyde starch nano cross-linked collagen hydrogel.
The present invention provides the following experimental data, all of which are experimental results obtained with starch as a representative polysaccharide:
as shown in fig. 1, the amphiphilic polymer dialdehyde polysaccharide-cholesterol polymer can be self-assembled in an aqueous solution to form dialdehyde polysaccharide nanoparticles, and the aldehyde content and the cholesterol grafting amount of the dialdehyde polysaccharide-cholesterol polymer determine the particle size and morphology of the dialdehyde polysaccharide nanoparticles.
As shown in FIG. 2, OCNPs/Col have more pore structures than the OS/Col and Col hydrogels, and pore size uniformity is the best of the three. The more uniform pore size distribution is advantageous for uniform cell growth and also for counteracting the pressure to be applied, thereby exhibiting higher mechanical strength.
As shown in FIG. 3, the OCNPs/Col hydrogel has a mechanical strength greatly improved compared with the OS/Col and Col hydrogels, and the compressive failure strength of the OCNPs/Col hydrogel can reach 70.8kPa, which is improved by about 26kPa compared with the OS/Col hydrogel.
As shown in fig. 4, the cell survival rate of L929 cells after 24h and 72h of incubation in different hydrogels was above 95%, and there was not much difference between the groups, indicating that the two modified collagen hydrogels were not substantially cytotoxic within the experimental concentration range.
As shown in FIG. 5, after L929 cells were co-cultured with the OCNPs/Col hydrogel for 24h, L929 cells survived the growth on the hydrogel surface in a typical spindle shape, indicating that the OCNPs/Col hydrogel has good cell compatibility.
It will be appreciated by those of ordinary skill in the art that the examples described herein are intended to assist the reader in understanding the manner in which the invention is practiced, and it is to be understood that the scope of the invention is not limited to such specifically recited statements and examples. Those skilled in the art can make various other specific changes and combinations based on the teachings of the present invention without departing from the spirit of the invention, and these changes and combinations are within the scope of the invention.
Claims (3)
1. A dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel is characterized in that: the collagen hydrogel is prepared by mixing and stirring uniformly a collagen aqueous solution with the mass fraction of 0.4-0.9% prepared from type I collagen and a dialdehyde polysaccharide nano-particle aqueous solution with the mass fraction of 3-6% prepared from dialdehyde polysaccharide nano-particles according to the mass ratio of 1 (0.5-1.5), and based on the chemical crosslinking reaction activity of Schiff base.
2. The method for preparing dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel according to claim 1, which comprises the following steps:
(1) preparing an aqueous collagen solution: dissolving I type collagen in 0.25M acetic acid aqueous solution to prepare collagen aqueous solution with the mass fraction of 0.4-0.9%, and then slowly adjusting the pH value of the collagen aqueous solution to be neutral under the ice-bath condition by using 2M sodium hydroxide solution;
(2) preparing dialdehyde polysaccharide nanoparticle solution: dissolving 1-5 parts by mass of polysaccharide in 50 parts by mass of molten imidazole under the condition of stirring in an oil bath at 100 ℃, and stabilizing for 30min to prepare a 1-10% clear and transparent polysaccharide solution;
adding cholesteryl chloroformate into the system, wherein the molar ratio of the cholesteryl chloroformate to polysaccharide molecular dehydration units (AGU) is (0.005-0.05): 1;
stirring for 1-3 h at 90-110 ℃, precipitating with excessive ethanol after the reaction is finished, filtering and washing for 4-6 times, and drying at 40-70 ℃ to obtain an amphiphilic polysaccharide derivative;
dispersing an amphiphilic polysaccharide derivative in water to obtain a polysaccharide derivative solution with the mass concentration of 1% -10%, adding sodium periodate, wherein the molar ratio of the sodium periodate to a polysaccharide molecular dehydration unit (AGU) is 0.1-1.0, carrying out a dark reaction for 2-5 h at 30-45 ℃, and carrying out dialysis and freeze drying after the reaction is finished to obtain a cholesterol grafted amphiphilic dialdehyde polysaccharide derivative; directly dissolving the amphiphilic dialdehyde polysaccharide derivative into deionized water to carry out self-assembly to obtain dialdehyde polysaccharide nano-particle aqueous solution with the mass fraction of 3-6%;
(3) preparation of collagen-based hydrogel: and (2) taking the collagen aqueous solution with the mass fraction of 0.4-0.9%, adding the dialdehyde polysaccharide nano-particle aqueous solution with the mass fraction of 3-6% under the ice bath condition, mixing and stirring uniformly according to the mass ratio of 1 (0.5-1.5), and standing at 30-37 ℃ for 24h to prepare the polysaccharide nano-crosslinked collagen hydrogel.
3. The method for preparing dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel according to claim 2, which is characterized in that: the polysaccharide is any one or mixture of starch, hydroxyethyl starch, sodium alginate, xanthan gum, pullulan, dextran, chitosan, guar gum and carrageenan.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010541765.1A CN111471193B (en) | 2020-06-15 | 2020-06-15 | Dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010541765.1A CN111471193B (en) | 2020-06-15 | 2020-06-15 | Dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111471193A true CN111471193A (en) | 2020-07-31 |
| CN111471193B CN111471193B (en) | 2021-03-16 |
Family
ID=71763888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010541765.1A Expired - Fee Related CN111471193B (en) | 2020-06-15 | 2020-06-15 | Dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111471193B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113577362A (en) * | 2021-08-10 | 2021-11-02 | 四川大学 | Nano zinc oxide/collagen-based antibacterial dressing and preparation method thereof |
| CN115197476A (en) * | 2022-07-18 | 2022-10-18 | 中国皮革制鞋研究院有限公司 | Bio-based aerogel and preparation method and application thereof |
| CN115518207A (en) * | 2022-09-27 | 2022-12-27 | 四川大学 | Heterogeneous double-layer collagen-based barrier membrane and preparation method and application thereof |
| CN117547653A (en) * | 2023-12-28 | 2024-02-13 | 深圳市迈捷生命科学有限公司 | Hyaluronic acid modified decellularized scaffold and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101845226A (en) * | 2010-04-15 | 2010-09-29 | 四川大学 | Dialdehyde carboxymethyl cellulose-collagen frozen gel and preparation method thereof |
| WO2012012359A1 (en) * | 2010-07-19 | 2012-01-26 | Actamax Surgical Materials, Llc | Method for making a polysaccharide dialdehyde having high purity |
| CN104262648A (en) * | 2014-09-18 | 2015-01-07 | 四川大学 | Collagen-based biomedical material by taking dialdehyde polyethylene glycol as cross-linking agent and preparation method thereof |
| CN104479150A (en) * | 2014-10-29 | 2015-04-01 | 上海大学 | Preparation method of multiple cross-linked polysaccharide injectable hydrogel |
| CN108003357A (en) * | 2017-11-13 | 2018-05-08 | 西南大学 | Catechu aldehyde crosslinked with collagen hydrogel and preparation method thereof |
| CN110408057A (en) * | 2019-07-16 | 2019-11-05 | 四川大学 | Suitable for biomedical DHPMC blended cross linking modified collagen and preparation method thereof |
| KR102067211B1 (en) * | 2019-03-28 | 2020-01-17 | 이광일 | Porous bone substitutes comprising dialdehyde starch and collagen, and method for manufacturing the same |
-
2020
- 2020-06-15 CN CN202010541765.1A patent/CN111471193B/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101845226A (en) * | 2010-04-15 | 2010-09-29 | 四川大学 | Dialdehyde carboxymethyl cellulose-collagen frozen gel and preparation method thereof |
| WO2012012359A1 (en) * | 2010-07-19 | 2012-01-26 | Actamax Surgical Materials, Llc | Method for making a polysaccharide dialdehyde having high purity |
| CN104262648A (en) * | 2014-09-18 | 2015-01-07 | 四川大学 | Collagen-based biomedical material by taking dialdehyde polyethylene glycol as cross-linking agent and preparation method thereof |
| CN104479150A (en) * | 2014-10-29 | 2015-04-01 | 上海大学 | Preparation method of multiple cross-linked polysaccharide injectable hydrogel |
| CN108003357A (en) * | 2017-11-13 | 2018-05-08 | 西南大学 | Catechu aldehyde crosslinked with collagen hydrogel and preparation method thereof |
| KR102067211B1 (en) * | 2019-03-28 | 2020-01-17 | 이광일 | Porous bone substitutes comprising dialdehyde starch and collagen, and method for manufacturing the same |
| CN110408057A (en) * | 2019-07-16 | 2019-11-05 | 四川大学 | Suitable for biomedical DHPMC blended cross linking modified collagen and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| WEIJUAN HUANG ET AL.: "On-Demand Dissolvable Self-Healing Hydrogel Based on Carboxymethyl Chitosan and Cellulose Nanocrystal for Deep Partial Thickness Burn Wound Healing", 《ACS APPLIED MATERIALS & INTERFACES》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113577362A (en) * | 2021-08-10 | 2021-11-02 | 四川大学 | Nano zinc oxide/collagen-based antibacterial dressing and preparation method thereof |
| CN113577362B (en) * | 2021-08-10 | 2022-04-19 | 四川大学 | Nano zinc oxide/collagen-based antibacterial dressing and preparation method thereof |
| CN115197476A (en) * | 2022-07-18 | 2022-10-18 | 中国皮革制鞋研究院有限公司 | Bio-based aerogel and preparation method and application thereof |
| CN115197476B (en) * | 2022-07-18 | 2023-08-22 | 中国皮革制鞋研究院有限公司 | Bio-based aerogel and preparation method and application thereof |
| CN115518207A (en) * | 2022-09-27 | 2022-12-27 | 四川大学 | Heterogeneous double-layer collagen-based barrier membrane and preparation method and application thereof |
| CN117547653A (en) * | 2023-12-28 | 2024-02-13 | 深圳市迈捷生命科学有限公司 | Hyaluronic acid modified decellularized scaffold and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111471193B (en) | 2021-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111471193B (en) | Dialdehyde polysaccharide nanoparticle crosslinked collagen hydrogel and preparation method thereof | |
| Mo et al. | Advances in Injectable and Self‐healing Polysaccharide Hydrogel Based on the Schiff Base Reaction | |
| Nezhad-Mokhtari et al. | An injectable chitosan-based hydrogel scaffold containing gold nanoparticles for tissue engineering applications | |
| Ma et al. | Synthesis and characterization of injectable self-healing hydrogels based on oxidized alginate-hybrid-hydroxyapatite nanoparticles and carboxymethyl chitosan | |
| Kostag et al. | Sustainable biomaterials based on cellulose, chitin and chitosan composites-A review | |
| Aguero et al. | Functional role of crosslinking in alginate scaffold for drug delivery and tissue engineering: A review | |
| CN111437438A (en) | Intelligent drug-loaded hydrogel responding to inflammatory microenvironment and preparation method and application thereof | |
| EP2310448B1 (en) | Three-dimensional nanocomposite materials consisting of a polysaccharidic matrix and metallic nanoparticles, preparation and use thereof | |
| Duceac et al. | Biopolymers and their derivatives: Key components of advanced biomedical technologies | |
| Guo et al. | Biofunctional chitosan–biopolymer composites for biomedical applications | |
| Long et al. | State-of-art review on preparation, surface functionalization and biomedical applications of cellulose nanocrystals-based materials | |
| Jaberifard et al. | A novel insoluble film based on crosslinked-starch with gelatin containing ZnO-loaded halloysite nanotube and bacterial nanocellulose for wound healing applications | |
| CN109796606B (en) | Self-healing hydrogel based on multiple dynamic chemical bonds and preparation method thereof | |
| JPH10502665A (en) | Wound healing agent | |
| El Knidri et al. | Chitin and chitosan: chemistry, solubility, fiber formation, and their potential applications | |
| Bi et al. | Homogeneous modification of chitin and chitosan based on an alkali/urea soluble system and their applications in biomedical engineering | |
| CN114874455B (en) | Construction method of neutral-dissolution modified collagen and gel with self-assembly capability and photocrosslinking capability | |
| EP0977780B1 (en) | Hetero-polysaccharide conjugates, s-inp polysaccharide gels and methods of making and using the same | |
| CN113185725B (en) | Method for rapidly preparing silver nanoparticle/gelatin composite hydrogel in situ | |
| Kavitha et al. | Cellulose-derived materials for drug delivery applications | |
| Hossain et al. | Fundamentals of chitosan for biomedical applications | |
| Wang et al. | Dextran | |
| CN115429935B (en) | Injectable cross-linked chondroitin sulfate hydrogel and preparation method thereof | |
| CN110408187B (en) | Injectable chitosan-based hydrogel with self-repairing property and high mechanical strength, and preparation method and application thereof | |
| CN114957720B (en) | Self-crosslinking antioxidant PCA-g-CMCS/OSA Schiff base hydrogel and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210316 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |